>
Obama Impeachment LIVE | US BIGGEST ARREST SHOCKS Nation! Tulsi DROPS BOMBSHELL
Will the Next First Turning Be to Technocracy?
Business Insider: Factcheck Your AI Stories Or Else
BREAKING EXCLUSIVE: Judge Delays Tina Peters Justice, Orders Colorado AG to Answer...
This "Printed" House Is Stronger Than You Think
Top Developers Increasingly Warn That AI Coding Produces Flaws And Risks
We finally integrated the tiny brains with computers and AI
Stylish Prefab Home Can Be 'Dropped' into Flooded Areas or Anywhere Housing is Needed
Energy Secretary Expects Fusion to Power the World in 8-15 Years
ORNL tackles control challenges of nuclear rocket engines
Tesla Megapack Keynote LIVE - TESLA is Making Transformers !!
Methylene chloride (CH2Cl?) and acetone (C?H?O) create a powerful paint remover...
Engineer Builds His Own X-Ray After Hospital Charges Him $69K
Researchers create 2D nanomaterials with up to nine metals for extreme conditions
Total color blindness, or achromatopsia, is generally an inherited disease caused by mutations in one of six different genes, with the majority of cases involving variants in either the CNGA3 or CNGB3 genes. The new gene therapy being trialed focuses on correcting a defect in the CNGA3 gene.
The treatment is somewhat similar to one of the first FDA-approved gene therapies, for vision loss, called Luxturna. These treatments attach a healthy functioning gene to a genetically modified harmless virus. The treatment is injected into a patient's eye and hopefully the correctly functioning gene begins producing whatever protein was previously missing, helping cure the condition caused by the defective gene.